Effect of dupilumab on allergic contact dermatitis and patch testing

Abstract

To the Editor: Although the pathogenesis of allergic contact dermatitis (ACD) has been classically thought to be driven predominantly by Th1, its complex pathophysiology is now accepted to include Th2, Th17, and Th22 pathways.1 Due to the involvement of the Th2 pathway and concomitant ACD diagnosis in many patients with atopic dermatitis (AD), numerous reports have recently described the use of dupilumab in patients with ACD.2 A systematic review was conducted to better understand the effect of dupilumab on ACD and patch testing results.